Scientists at the First Affiliated Hospital of Guangzhou Medical University have unveiled NeoPred, a novel AI framework integrating dual-phase CT imaging and clinical data to non-invasively predict major pathological response of non-small cell lung cancer (NSCLC) to neoadjuvant chemo-immunotherapy. By enabling preoperative evaluation, NeoPred offers potential to tailor treatment strategies dynamically, enhancing precision oncology in lung cancer care. This advancement could improve surgical and systemic therapy decisions, reducing unnecessary exposure and optimizing clinical outcomes.